Alaunos Therapeutics to present data on its hunTR TCR Discovery platform

Alaunos Therapeutics announced a poster presentation highlighting the potential of the Company’s human neoantigen T-cell receptor platform to expand its TCR Library. The data will be presented at the Society for Immunotherapy of Cancer’s, SITC, 37th Annual Meeting in Boston, Massachusetts from November 8-12, 2022. Title: "hunTR: a hyperplex platform for the discovery of neoantigen-reactive T-cell receptors." In the study, Alaunos evaluated ~525,000 TCR+HLA+neoantigen combinations in nine patients across colorectal, endometrial and breast cancers. All patients screened had at least one detectable neoantigen-reactive TCR, including one shared KRAS-Q61H mutation and 21 personal mutations. Of these, 78% were restricted by HLA Class II while 22% were restricted by HLA Class I. A median reactive hit rate of 13% was achieved per patient with an average of three unique neoantigen specificities. In subsequent patients screened only for KRAS mutations, multiple patients had TCRs reactive to KRAS-G12V, further demonstrating the ability of hunTR to discover exclusively owned hotspot mutation-reactive TCRs that could be added to the clinical library. The Company plans to continue to expand the application of hunTR to screen for additional shared KRAS, TP53, and EGFR mutations to rapidly advance new TCR library candidates from the lab through to clinical translation. In addition, hunTR may be suitable for personalized TCR-T therapies, enabling mutation-targeted cell therapy for most solid tumor cancers.